Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GRI Bio Inc GRI

Healthcare Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in... see more

Recent & Breaking News (NDAQ:GRI)

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference

GlobeNewswire October 11, 2023

GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions

GlobeNewswire October 5, 2023

September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease

Accesswire September 29, 2023

GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?

Accesswire September 1, 2023

GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign

Newsfile August 29, 2023

GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus

Accesswire August 25, 2023

GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR

GlobeNewswire August 23, 2023

JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series

Accesswire August 16, 2023

GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

GlobeNewswire August 7, 2023

GRI Bio (NASDAQ: GRI) to Present at Benzinga's Virtual Biotech Conference

GlobeNewswire August 3, 2023

JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th

Accesswire July 26, 2023

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor - The GRI Opportunity Spotlight Event

GlobeNewswire July 24, 2023

GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series

GlobeNewswire July 5, 2023

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

GlobeNewswire June 27, 2023

GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

GlobeNewswire June 15, 2023

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

GlobeNewswire June 13, 2023

GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

GlobeNewswire May 22, 2023

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event

GlobeNewswire April 27, 2023